Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Table 1 Significance of KRAS mutations in retrospective single arm studies and randomized prospective trials

Published studies	n	% KRAS mutations	Significant correlations
Retrospective single arm studies
Moroni et al[16]	31	32	None
Lièvre et al[13]	30	43	RR, mOS
Lièvre et al[18]	89	27	RR, PFS, mOS
De Roock et al[17]	66	40	RR, mOS
Randomized prospective trials
Amado et al[12]	427	43	RR, PFS, mOS
Tol et al[22]	256	38	RR, PFS
Van Cutsem et al[19]	277	38	RR, PFS, mOS
Bokemeyer et al[20]	233	42	RR, PFS
Hecht et al[21]	865	40	PFS, mOS
Douillard et al[23]	1096	40	RR, PFS

RR: Response rate; mOS: Median overall survival; PFS: Progression-free survival.